News – Page 661 – Endpoints News

Tibsovo clears another hurdle for Servier, but can it make Agios' old drug profitable?

4 years ago

Roivant bumps stake in Immunovant with a $200M deal. But with M&A off the table, shares crater

4 years ago

Watch out GlaxoSmithKline: AstraZeneca's once-failed lupus drug is now approved

4 years ago

How the biopharma industry is helping to pay for the bipartisan infrastructure bill

4 years ago

Covid-19 roundup: Regeneron's mAB gets expanded EUA; mRNA drugmakers spike price of vaccines in EU supply deal

4 years ago

Ipsen continues its shopping spree with a $1B-plus deal for Exicure's next-gen oligonucleotides

4 years ago

Not all mRNA vaccines are created equal. Does it matter?; Neuro is back; Private M&A affair; and more

4 years ago

Six more biotechs price public debuts just before the start of the weekend

4 years ago

AbbVie, riding the Aduhelm afterglow, handpicks beta amyloid drug for further R&D as it bails on tau

4 years ago

When is a drug intended for a specific use? Not just when it's promoted as such, FDA says in long-awaited final rule

4 years ago

Top Gilead cancer researcher jumps to a startup as Dan Chen exits; Ardelyx gets that CRL we've been waiting for

4 years ago

Covid-19 roundup: Brazil backs out of Sputnik V vaccine deal; White House implements new mask, vaccine mandates

4 years ago

Roche China CEO preps for a move to Merck KGaA while US Merck adds to C-suite; Succession plan finalized for EVPs ...

4 years ago

BeiGene looks to carve out more space in the US market, setting up BTK drug for 2nd blood cancer nod

4 years ago

Biogen launches Phase IV trial to see just how well Aduhelm works in the real world

4 years ago

FDA sends 2nd noncompliance notice for company failing to post trial results as crackdown ramps up

4 years ago

Takeda and Frazier team up again to launch a spinout — this time focused on a late-stage vaccine

4 years ago

Gilead lands in North Carolina with a plan to hire 300 for new center

4 years ago

On the heels of Takeda pact, PeptiDream kicks off $2.2B deal to broaden Alnylam's siRNA delivery scope

4 years ago

Cavazzoni in the hot seat: House committee grills CDER director on neuro drugs

4 years ago

Shooting straight for Venclexta, a seasoned Chinese CEO has global dreams for his startup

4 years ago

Gunning for Biogen’s multibillion dollar market, Eli Lilly cuts up another batch of Alzheimer’s data

4 years ago

Royalty Pharma competitor stirs the pot with plans for $750M IPO

4 years ago

Could a fourth lead drug finally bring Infinity an approval?

4 years ago

First page Previous page 658 659 660661662 663 664 Next page Last page